Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy
Abstract
The main target of this work is to examine blood clearance and external exposure for 177 Lu-DOTATATE compared with new emerging 177 Lu-PSMA therapy. Blood clearance and radiation exposure of 31 patients treated with 5.5 ± 1.1 GBq 177 Lu-DOTATATE were compared to those of 23 patients treated with 7.4 GBq 177 Lu-PSMA. Dose rates were measured at several distances and time points up to 120 h after treatment. Blood samples were collected conjunctively after infusion. Caregiver's cumulative dose was measured by means of an OSL (optically stimulated luminescence) dosimeter for 4-5 days and medical staff's dose was also estimated using electronic personal dosimeters. Finger dose was determined via ring TLD (Thermoluminescence Dosimeter) for radiopharmacists and nurses. Dose rates due to 177 Lu-DOTATATE at a distance of 1 m, 4 h and 6 h after infusion, were 3.0 ± 2.8 and 2 ± 1.9 µSv/(h GBq), respectively, while those due to 177 Lu-PSMA were 3.1 ± 0.8 and 2.2 ± 0.9 µSv/(h GBq). Total effective dose of 17 caregivers was 100-200 µSv for 177 Lu-DOTATATE therapy. Mean effective doses to nurses and radiopharmacists were 5 and 4 µSv per patient, respectively, while those for physicists and physicians were 2 µSv per patient. For 177 Lu-DOTATATE, effective half-life in blood and early elimination phase were 0.31 ± 0.13 and 4.5 ± 1 h, while they were found as 0.4 ± 0.1 and 5 ± 1 h, respectively, for 177 Lu-PSMA. The first micturition time following 177 Lu-DOTATATE infusion was noted after 36 ± 14 min, while the second and third voiding times were after 74 ± 9 and 128 ± 41 min, respectively. It is concluded that blood clearance and radiation exposure for 177 Lu-DOTATATE are very similar to those for 177 Lu-PSMA, and both treatment modalities are reasonably reliable for outpatient treatment, since the mean dose rate [2.1 µSv/(h GBq)] decreased below the dose rate that allows release of the patient from the hospital (20 µSv/h) after 6 h at 1 m distance.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The effective half-life of [177Lu]Lu-DOTA-TATE in blood in a study with 31 patients was 0.31 ± 0.13 h.
“The effective half-life in blood in a study with 31 patients was determined to be 0.31 ± 0.13 h [33].”
From Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy (2019) · cites this paper as [33]
Cites
Zaknun, J. J., Bodei, L., Mueller‐Brand, J., Pavel, M. E., Baum, R. P., Hörsch, D., O'Dorisio, M. S., O’Dorisiol, T. M., Howe, J. R., Cremonesi, M., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2330-6 · Cited by 823 · see citing works
[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients
Kwekkeboom, D. J., Bakker, W. H., Kooij, P. P. M., Konijnenberg, M., Srinivasan, A., Erion, J. L., Schmidt, M. A., Bugaj, J. E., de Jong, M., & Krenning, E. P. (2001) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590100574 · Cited by 469 · see citing works
Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Kwekkeboom, D. J., Kam, B. L. R., van Essen, M., Teunissen, J. J. M., van Eijck, C. H. J., Valkema, R., de Jong, M., de Herder, W. W., & Krenning, E. P. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0078 · Cited by 465 · see citing works
Kabasakal, L., AbuQbeitah, M., Aygün, A., Yeyin, N., Ocak, M., Demirci, E., & Toklu, T. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3125-3 · Cited by 208 · see citing works
Self-citationA technique for the absolute measurement of activity using a gamma camera and computer
Fleming, J. S. (1979) · Physics in Medicine and Biology · doi:10.1088/0031-9155/24/1/017 · Cited by 154 · see citing works
Localisation and mechanism of renal retention of radiolabelled somatostatin analogues
Melis, M. L., Krenning, E. P., Bernard, B. F., Barone, R., Visser, T. J., & de Jong, M. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1793-0 · Cited by 136 · see citing works
Preclinical and Clinical Studies of Peptide Receptor Radionuclide Therapy
Pool, S. E., Krenning, E. P., Koning, G. A., van Eijck, C. H. J., Teunissen, J. J. M., Kam, B. L. R., Valkema, R., Kwekkeboom, D. J., & de Jong, M. (2010) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2009.12.001 · Cited by 97 · see citing works
Swärd, C., Bernhardt, P., Ahlman, H., et al. (2010) · World Journal of Surgery · doi:10.1007/s00268-009-0387-6 · Cited by 68 · see citing works
Demır, M., Abuqbeitah, M., Uslu, L., et al. (2016) · Journal of Radiological Protection · doi:10.1088/0952-4746/36/2/269 · Cited by 56 · see citing works
Self-citationPractical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate.
Bakker, W. H., Breeman, W. A., Kwekkeboom, D. J., et al. (2006) · PubMed · Cited by 44 · see citing works
Radiation protection for accompanying person and radiation workers in PET/CT
Demır, M., Demir, B., Sayman, H. B., et al. (2010) · Radiation Protection Dosimetry · doi:10.1093/rpd/ncq497 · Cited by 43 · see citing works
Radiation exposure for ‘caregivers’ during high-dose outpatient radioiodine therapy
Marriott, C., Webber, C. E., & Gulenchyn, K. Y. (2006) · Radiation Protection Dosimetry · doi:10.1093/rpd/ncl084 · Cited by 37 · see citing works
Outpatient therapeutic nuclear oncology
Turner, J. H. (2012) · Annals of Nuclear Medicine · doi:10.1007/s12149-011-0566-z · Cited by 33 · see citing works
Radionuclide Peptide Cancer Therapy
(2013) · CRC Press eBooks · doi:10.3109/9781420016727 · Cited by 21 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Hennrich, U., & Kopka, K. (2019) · Pharmaceuticals · doi:10.3390/ph12030114 · Cited by 440 · see citing works
- Authors
- Abuqbeitah, M., Demir, M., Uslu-Beşli, L., Yeyin, N., & Sönmezoğlu, K.
- Affiliations
- Istanbul University-Cerrahpaşa (TR)
- Corresponding author
- Abuqbeitah, Mohammad
- Venue
- Radiation and Environmental Biophysics
- Published
- 2017-11-17
- Volume
- 57
- Issue
- 1
- Pages
- 55-61
- ISSN
- 0301-634X (ISSN-L)
- 1432-2099
- OpenAlex
- W2768886125
- Cited by
- 31
- References
- 14
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 4 · 2023: 7 · 2022: 1 · 2021: 2 · 2020: 1 · 2019: 4 · 2018: 3
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Radiation and Environmental Biophysics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- International Atomic Energy Agency
- Istanbul Üniversitesi-Cerrahpasa
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiation Dose and Imaging
- Health Sciences › Health Professions › Radiological and Ultrasound Technology › Radioactivity and Radon Measurements
- Keywords
- 177Lu-DOTATATE, 177Lu-PSMA, blood clearance, occupational radiation exposure, radionuclide therapy, effective half-life, radiation dose rate, micturition, urinary excretion, radiopharmaceuticals, dosimetry, PSMA-targeted therapy, somatostatin receptor imaging, prostate cancer treatment
- MeSH terms
- Dipeptides, Health Personnel, Heterocyclic Compounds, 1-Ring, Humans, Lutetium, Organometallic Compounds, Tissue Distribution, Octreotide, Occupational Exposure, Prostate-Specific Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
